Good day and thank you for standing by. Welcome to the Certara Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, David Deuchler, Head of Investor Relations. Go ahead.

Good afternoon, everyone. Thank you all for participating in today's conference call. On the call from Certara, we have William Feehery, Chief Executive Officer; John Gallagher, Chief Financial Officer. Earlier today, Certara released financial results for the quarter ended June 30, 2024. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements and actual results may differ materially from those expressed or implied in the forward-looking statements. Please refer to slide 2 in the accompanying materials for additional information, which you can find on the company's Investor Relations website. In their remarks or responses to questions, management may mention some non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are available on the recent earnings press release available on the company's website. Please refer to the reconciliation tables in the company materials for additional information. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, August 6, 2024. Certara disclaims any obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise. With that, I'll turn the call over to William.

Thank you, David, and good afternoon, everyone. Thank you for joining Certara's second quarter earnings call. John and I will begin with prepared remarks, and then we will take your questions. Certara's second quarter performance reflects continued strength in software and a more challenging environment in services. We have found that the pace of recovery in the market demand has been relatively mixed. There are positive signs among some biotechs, especially those in the clinical stage, but we see continued caution in the spending patterns of some Tier 1 clients. This has affected our business segments in different ways. Our software business is growing with new products, new seats and new clients as customers see the potential for our products to reduce costs and improve development outcomes. However, our services business is more dependent upon the overall progress of projects in the global development pipeline where there has been reduced spending across the industry and which has impacted our near-term commercial opportunities. That said, our conversations with customers indicate high interest in biosimulation over the long term and specifically in Certara's software and services. Second quarter total revenue grew 3% to $93.3 million, which was slightly below our internal expectations. Underlying this was 13% growth in our Software segment and negative 3% growth in our Services. During the quarter, Certara made efforts to optimize the allocation of resources across the business, including cost reduction actions to better position ourselves for the balance of 2024 and beyond. As we look to the future, we were encouraged to see our total bookings in the second quarter were $98.9 million, which grew 15% year-over-year. Throughout the quarter, the pace of commercial activity in our services business progressed towards the lower end of our expectations with Tier 3 customers outperforming and Tier 1 customers underperforming. We have not yet seen an inflection point at the market level in services demand, but we have seen some green shoots in the Tier 3 customer base and are encouraged by that customer group heading into the second half of the year. We believe that our Tier 1 customers have continued to evaluate spending priorities and pipeline development initiatives throughout the first half of the year. This has resulted in slower spending and elongated decision-making, impacting our services business. We are encouraged by 14% growth in services bookings for the second quarter. As we continued our strong performance in software, reemerging strength in biotech customers, and the normal seasonality of our business, we continue to have confidence in our full-year outlook, which we are reiterating today. The environment we have seen year-to-date falls within the range of outcomes we anticipated when we initiated 2024 guidance earlier this year. As we assess the remainder of the year, we believe disciplined commercial strategy, new product releases, and a stable end market keep the revenue guidance range achievable with the upper end of the guidance range possible with an improving end market outlook, but we are tracking to the lower half of the revenue guidance range, given what we've seen during Q2 with our Tier 1 services customers. Next, let's touch on some recent highlights at Certara. In the rapidly changing biopharma landscape, we're engaging with key players across the sector. During our inaugural client summit called Certainty, we brought together biosimulation experts to discuss our offerings in an interactive environment. Over 250 clients joined various tracks tailored to specific applications, networking and engaging with the Certara team. This included hands-on workshops for Simcyp, Phoenix, and Pinnacle 21, plus a preview of the CoAuthor AI regulatory writing software. The summit proved to be an excellent platform for solidifying customer relationships and promoting model-informed drug development. We have also continued to focus on investments that support the long-term adoption of biosimulation. Last month, we announced an agreement to acquire Chemaxon, a leading provider of cheminformatics software used in the discovery phase of drug development. This acquisition is expected to close in the fourth quarter, subject to customary closing conditions. Used by 18 of the top 20 pharma companies, Chemaxon's tools span the design, make, test, and analyze framework, which is used to make lead optimization and pipeline development prioritization decisions. By integrating these tools with Certara's biosimulation products and artificial intelligence technology, we can enhance the use of model-informed drug development in the discovery and lead optimization phases. Chemaxon is expected to generate 2024 software revenues of over $20 million with our team of over 200 employees, including more than 75 software developers. Their 2024 adjusted EBITDA margin is below Certara's corporate average, but we have a roadmap to achieve margins approaching Certara's corporate average adjusted EBITDA margin by the end of 2025. In the second quarter, we continued to make progress in developing new software products and product features and integrating AI across our portfolio. In early June, we released the 23rd version of Simcyp, which included new features such as advanced biomarker modeling to predict drug-drug interaction risks and expanded biopharmaceutics capabilities. Additionally, the new version of Simcyp aligns with recent FDA guidelines, covering pH-dependent drug-drug interactions and therapeutic proteins that should help ensure smoother regulatory processes. We also announced the highly anticipated full commercial launch of our CoAuthor regulatory writing software at DIA 2024. CoAuthor leverages generative AI to accelerate the drafting of regulatory submissions and has demonstrated improved efficiency to first draft by greater than 30%. CoAuthor is another example of how Certara is using AI technology acquired in the Vyasa transaction to develop impactful products that can ultimately drive further market penetration. Early customer feedback has been very positive and we expect the product will generate notable commercial interest as the year progresses. Wrapping up, we are working diligently to improve growth and profitability of the businesses in the second half of the year. There have been several exciting developments related to our software products this year, and we announced a strategic acquisition that will help accelerate industry adoption of model-informed drug development, particularly in the discovery phase with strong synergistic growth opportunities. We continue to attract new customers and add new product features that impact drug development timelines and efficiencies. As I look forward to the rest of the year and beyond, I am confident in the investments we are making in our business and that they will translate to long-term growth. With that, I will now hand things over to John, to discuss our financial results in more detail.

Thank you, William. Hello, everyone. Total revenue for the three months ended June 30, 2024, was $93.3 million, representing year-over-year growth of 3% on a reported basis and 3% on a constant currency basis. Software revenue was $38.2 million in the second quarter, which increased 13% over the prior year period on a reported basis and on a constant currency basis. The growth in the quarter was driven by biosimulation software and Pinnacle 21. Ratable and subscription revenue accounted for 65% of second quarter software revenues, up from 57% in the prior year period. Software bookings were $41.8 million in the second quarter, which increased 17% from the prior year period. Trailing 12-month software bookings were $145.5 million, up 11% year-over-year. The software net retention rate was 108%, which is consistent with our long-term growth profile. Looking at our software bookings performance by tier, we saw very strong performance in both Tier 1 and Tier 3 customer segments, driven by continued adoption of our software. Now, turning to services revenue, which was $55.1 million in the second quarter, down 3% versus the prior year period on both a reported basis and a constant currency basis. Our services business continues to recover following a period of cautious spending among our customers. We were pleased to see improving performance in the Tier 3 customer base, which we anticipate will continue, while Tier 1 customers underperformed our internal expectations on cautious spending, as Bill mentioned earlier. Technology-driven services bookings in the second quarter were $57.1 million, which increased 14% from the prior year period. TTM services bookings were $262.9 million, down 2% as compared to the prior year. Total cost of revenue for the second quarter of 2024 was $39.8 million, an increase from $36.2 million in the second quarter of 2023, primarily due to a $2.8 million increase in employee-related expenses, a $0.5 million increase in stock-based compensation, and a $0.8 million increase in software amortization. Total operating expenses for the second quarter of 2024 were $62.5 million, an increase from $41.2 million in the second quarter of 2023. Drivers of increased operating expenses included higher employee-related expenses due to recent acquisitions and planned investments in sales and marketing and research and development, along with higher stock-based compensation transaction expenses related to the debt refinancing. Adjusted EBITDA for the second quarter of 2024 was $26.3 million, a decrease from $32.4 million in the second quarter of 2023. Adjusted EBITDA margin was 28.2%. We expect sequential improvement in adjusted EBITDA margin in the third quarter due to the realigned resources and cost reductions mentioned earlier. And so we remain confident in our full-year adjusted EBITDA margin guidance of 31% to 33%. As Bill said in his remarks, after evaluating investments and cost allocation in the first half of the year, we have realigned resources to be more consistent with where we see the largest growth opportunities. Our focus remains on investing for growth, particularly in software and AI, while ensuring underperforming areas of the business are appropriately structured. Wrapping up the income statement, net loss for the second quarter of 2024 was $12.6 million compared to net income of $4.7 million in the second quarter of 2023. Reported adjusted net income for the second quarter of 2024 was $11.4 million compared to $18.4 million for the second quarter of 2023. Diluted loss per share for the second quarter of 2024 was $0.08 compared to earnings per share of $0.03 in the second quarter of 2023. Adjusted diluted earnings per share for the second quarter of 2024 was $0.07 compared to $0.12 for the second quarter of last year. Moving to the balance sheet, we finished the quarter with $224.6 million in cash and cash equivalents. As of June 30th, 2024, we had $296.7 million of outstanding borrowings on our term loan and full availability under our revolving credit facility. During the quarter, we took action to refinance our revolving credit facility and term loan in an effort to reduce our interest expense and push out maturities five to seven years, respectively. These actions taken are expected to be accretive to fiscal 2025 EPS by $0.01 and by $0.02 from fiscal years '26 through '31. We are reiterating our guidance for the full year 2024, excluding any impact from Chemaxon as follows: we expect total revenue in the range of $385 million to $400 million, representing growth of 9% to 13% compared with 2023. Through the first half of 2024, we are tracking toward the lower half of the revenue range. We expect to grow adjusted EBITDA on a dollar figure basis in 2024 and expect an adjusted EBITDA margin in the range of 31% to 33%. Upon the closing of the Chemaxon transaction, we do expect to maintain our adjusted EBITDA margin guidance of 31% to 33%. We expect adjusted EPS in the range of $0.41 to $0.46 per share, fully diluted shares in the range of $160 million to $162 million and a tax rate in the range of 25% to 30%. I will now turn the call back over to our CEO, William Feehery for closing remarks.

Thank you, John. To summarize our message today, we are pleased with the many exciting developments at Certara in the second quarter, and we remain focused on executing our growth and profitability goals in 2024. There's a lot to be excited about at Certara as we advance biosimulation with our innovative technology. Operator, can you please open the line for questions.

Our first question comes from Jeff Garro from Stephens. Your line is now open.

Yes, good afternoon. Thanks for taking the questions. Maybe start on the guidance and I appreciate the direction there that you're tracking towards the lower half of the range on revenue. But maybe you could give some more comments on what gives you confidence that won't slip below the bottom end of that range.

Yes, hi Jeff, this is John. I can take that one. So, as you pointed out, and we said in the remarks, we're tracking towards the lower half of the guidance range given the current environment, and that's primarily due to the performance that we've seen in Q2 on the Tier 1 services customers. So they are tracking below what our expectations were. But that being said, we do expect software to continue to do well. As we mentioned, we're seeing good signs in Tier 3 customers, both in software and in services. And then if you take those together with typical seasonality that we've seen, including last year. So last year was a tough end market environment, and we saw typical seasonality in Q4, then that's what gives us the confidence on maintaining the range.

Excellent. That helps. And then maybe to hit the profitability side a little bit, I was hoping you could speak a little bit more to the cost reductions. Maybe help us by calling out which line items will see more of an impact? And then how we should think about the run rate those actions on an annualized basis versus the impact we'll see in Q3? And then more strategically, why any cost reductions taken in recent weeks or months, would impact the long-term growth opportunity for the company. Thanks.

Yes, we are reallocating resources to focus on the areas with the greatest growth potential. Our investment is concentrated on software and integrating AI while also implementing cost-saving measures in underutilized or underperforming areas of the business. This gives us confidence in our EBITDA margin guidance because these actions have already been taken and are reflected in our profit and loss statement. We expect these improvements to continue in both Q3 and Q4. Specifically, you can anticipate a benefit of approximately 500 basis points on revenue costs, with around 300 basis points affecting the cost of sales and about 200 basis points impacting operating expenses.

Maybe Will can take the last part around why the cost actions will impact the growth opportunity from here?

Thank you, Jeff. I appreciate it. We have adjusted based on the current market conditions. However, we have not reduced our investments in new products or in the long-term vision and health of Certara. As John mentioned, we are maintaining our investments in AI. We made some minor adjustments based on observed market demand in the short term, which we felt was a prudent choice, and we opted not to fill certain positions we had planned to hire for. We are committed to achieving our EBITDA margin guidance, and these actions were taken to help us reach that goal.

Great. Thanks for taking the question.

Our next question comes from David Windley from Jefferies. Your line is now open.

Hi, thank you. Good afternoon. I appreciate you taking my questions. I wanted to continue from where Jeff left off. Five hundred basis points is quite significant. If I look at the bigger picture, you started this year with your bookings trajectory facing some challenges and made the decision to invest more in growth, particularly in R&D and sales and marketing. In your 2024 business update slide, you mention that you are reducing spending in sales and marketing. I would like to understand the overall context better. Bill, I value your comments on the current environment, but I am curious about what has changed in the six months since you decided to increase some investments as you approached 2024.

Thanks, David. I'll begin, and then John can provide some numbers. What we see as we step into 2024 is a significant opportunity to further invest in software, especially in the AI initiatives that began when we acquired the asset and continued into last year. We are still moving forward with these investments, which are starting to yield positive results. We recently launched a product that is just starting to gain traction and has been well accepted by customers. Therefore, we view these investments as beneficial and worth pursuing. In the first half of the year, we noticed some initial softness in Tier 3, but that has improved over time. However, there is still some softness in Tier 1, particularly in services. This allows us to adjust our cost structure in services more easily compared to our long-term commitments in software. Consequently, we made some necessary adjustments there. John, feel free to add your insights.

Yeah, yeah, Bill. Hi, David. I think what we did there is we were slowing some headcount growth. So that's a piece of it. And we were really targeting, as Bill was just saying, we're targeting the underutilized areas of the business to take some costs out where it wasn't efficient. And so at the time that we did the guidance on the fourth quarter call, we said that we had put together investments, and we had expected the plan to play out in a certain way. And some of the plan isn't playing out in the way that we expected at the time that we did that guidance. And we said if that was the case, we would need to take actions to maintain the EBITDA, and we've done that, and we've done that as you would expect us to, basically because of what we saw happening with Tier 1 services customers.

Okay. And if I could follow-up on that, good segue there. In thinking about Services, my intuition is that Services with your big customers would maybe lean a little bit more toward regulatory end market access and smaller customers would lean a little bit more toward biosim services, is that right such that like the services weakness that you're seeing in Tier 1 is in a different area than the weakness you maybe had seen in small, and that's improving now in small? Or is it really in the same area, all in kind of biosim?

It's really both. So, the services weakness that we're seeing is both in regulatory and in biosim services.

Okay. Great. Thanks. I’ll follow-up offline. Thank you.

Thank you. Our next question comes from Michael Cherny from Leerink Partners. Your line is now open.

Great. Thank you. This is Dan Clark on for Mike. First from us, how are you guys thinking about pricing on the services side just with these elongated customer conversations on the Tier 1 side, like how do you kind of balance discipline in pricing or price increases and getting deals done? Thanks.

Yes, I'd say that the price increases are more modest, given the environment that we're in and the cautious spend and the slower decision-making. We are still increasing price, but we're increasing more modestly.

And then just a quick modeling question. The customer summit you guys held in 2Q, how should we think about the expense in the sales and marketing lines as you can kind of model the rest of the year there? Thank you.

Yes. So as we were just saying, the first half and the 2Q sales and marketing expenses is increasing based on the investment that we made and to some degree because of the M&A transactions that we brought in. We have taken actions as we were just discussing that are going to slow headcount growth and would slow the headcount growth that we have on our line item also.

Thank you. Our next question comes from Michael Ryskin from BofA. Your line is now open.

Hi. It’s Wolf on for Mike. Thanks for taking question, guys. I kind of want to pick back up on the guidance theme, but perhaps just take a step back to end markets overall. I think we all kind of saw Smith Biotech funding take a sequential step down in 2Q and thought that CRO or larger pharma spend with CROs and the like seemed fairly stable. Obviously, you're kind of pointing to an opposite dynamic from that. So I'm just wondering if you can talk to how the tenor of your conversations with those two customers evolved over the course of the quarter.

Yes. Thanks for your question. I think what we saw was there was a pickup in the small biotech funding in the first quarter. And then I think we believe that we saw that start to flow through in the second quarter. So there's some lag between what happens in funding and obviously, when it reaches us. But the pickup was welcome because we had seen weakness in that segment for really quite some quarters now. So it was good to see them come back. I think on the larger customers, we saw just more caution around spending. It's certainly true in past years, we've seen pickups in the second half and particularly as you go into the very end of the year as customers want to spend their budget. So we're sort of cautiously watching what happens to that market. And obviously, we factored that into the guidance that we gave.

Got it. Thank you. And then just one more kind of strategic one. Could you talk to the rationale behind the Chemaxon deal? Just interested in your kind of intent in expanding more into the preclinical space and what opportunities that you see there?

Yes. Thanks for the question. So Chemaxon is an important acquisition for us. I think a lot of people have asked me for a while, what are some areas that we're interested in expanding in? And we've always talked about preclinical and the discovery space as being areas that are ripe for biosimulation to make a bigger impact. Most of the biosimulation help that we provide our clients in Certara has been sort of preclinical and then especially in the clinical phase, and we do really well there. But it's important to be able to help our clients make informed decisions on which drugs to take forward and which leads to optimize. We see an opportunity there to make a bigger impact on the overall success of drug development, and Chemaxon has quite a number of tools that we believe that we can integrate into a wider suite of biosimulation tools going forward to enable that.

Wonderful. Thanks for the answers guys.

Thank you. Our next question comes from Luke Sergott from Barclays. Your line is now open.

Thanks for the question. Following up on Wolf's inquiry about biotech and its funding, what are the expectations for the remainder of the year? I understand you anticipate that the first quarter's momentum will continue into this quarter. What is included in your guidance for the rest of the year regarding the performance of those biotech companies?

Yes. Thanks for the question, John, do you want to take that one?

Yes, I got it, Bill. The way to think through the customer tiering on the biotech for the remainder of the year is we are not planning an uplift on Tier 3. We were pleased to see a bit of an uptick in Q2, but we have the guide really contemplates a continuation of just sort of stability on the Tier 3 customer base. But that being said, I mentioned earlier, we do anticipate typical seasonality. So turning to Tier 1 customers, the guide does contemplate a pickup in Tier 1 customer activity Q4, which is what we've seen historically. And importantly, we saw last year during that time also that had a difficult end market environment. So that's the only piece of seasonality or uptick that we really have planned into the guidance.

Got you. That’s really helpful. And then a follow-up on just software bookings. You mentioned maybe some strength was driven by the expansion of biosimulation to new customers. Is this mostly driven by new offerings? And I'm kind of curious if CoAuthor was a significant portion of bookings due to the new unveil or is this more of a side effect of the commercial reorg? And could you just give us an update on the progress there and how it's trending versus your expectations on synergies? Thanks.

Yes. Thanks. And maybe I'll start with that one, John. So we saw nice growth in our core software products, particularly Simcyp and Pinnacle 21, so that was good to see. CoAuthor was just sort of fully launched at the end of June, so it's a bit too early for that to be a significant impact on our bookings. But we did have a pretty big launch, and we've received quite a bit of interest for that product. So let's watch as we go forward, but it didn't play a significant effect on the numbers that we reported for the quarter. I'd say across the board, we saw a lot of interest in AI. There's been a steady stream of feature launches and product extensions in our Simcyp family, which has contributed a lot to the growth. So those are the kind of areas that we saw the best growth.

Awesome. Appreciate it.

Thank you. Our next question comes from Joe Vruwink from Baird. Your line is now open.

Great. Hi, everyone. If the smaller customers are buying biosimulation software and starting to become more visible in the services pipeline, is there any history for you to say that your large customers tend to follow the small customers within a matter of some quarters or is just the current regulatory environment that the large customers are dealing with so different that it kind of muddies any historical comparisons you might make?

Thank you, Joe. That's a great question. We observe that the market is functioning somewhat differently now. We believe that large customers are currently reassessing their extensive portfolios of drugs, determining which ones to advance and which ones to set aside. This situation does not particularly apply to smaller customers, most of whom are focused on securing funding for a single drug or platform. Therefore, we don't necessarily see a direct correlation as you mentioned. It is true that biotechs often experience mergers and acquisitions with larger clients eventually, but we do not anticipate that impacting our outlook for the rest of the year.

Okay. Thank you. And then just a tougher backdrop specifically for regulatory services, any risk that that carries over to your regulatory focused software offerings, or you mentioned at the start of the call, just large customers very focused on cost reductions and efficiencies. Is a tougher environment you're seeing on the services side actually beneficial in bringing up things like Pinnacle or maybe it creates an even more favorable launch environment or something like CoAuthor?

CoAuthor is a fascinating tool. In our internal testing, we've observed significant time savings in creating regulatory documents. In any situation, substantial cost reductions like that are compelling. That's why we're receiving positive feedback. Our experience in the regulatory business has informed the development of this product, which has been shaped by the actual users of the software. This insight has helped us design something genuinely beneficial in that market. I would add that we continue to see consistent spending on software from customers, many of whom view it as an ongoing investment in their infrastructure. As long as they pursue research and development, they will require most of our software. Discussions revolve around renewal rates and the introduction of new features and enhancements. This is one reason why we are currently seeing a robust market, while services have become more project-oriented due to adjustments in portfolios, with some drugs being halted and others initiated, leading to some disruption in the flow of projects coming our way, which will have an impact this year.

Okay. I'll leave it there. Thank you very much.

Our next question comes from Max Raines from William Blair. Your line is now open.

Hi. Good afternoon. Thanks for taking our questions. I wanted to ask you a question along the same line as Wolf's question earlier. So on the services side, given we've seen clinical CROs flow out pretty well, is it fair to assume that at least a chunk of these programs in large pharma moving forward, but they're electing to do so maybe without your consulting services? Or do you really think it's more a function of the fact that you're missing now and on bidding and working on these clinical programs that are actually being paused and reevaluated? And therefore, maybe there's a potential for you all to still recognize revenue from these programs in the back half of the year or 2025 as they potentially move forward?

Yes. We do believe that, and in addition, we point to the fact that we did see an uptick in services bookings in the second quarter. So I would say it's too early to call a huge recovery in the market, but we are seeing improvement in the overall environment as we move forward to the second half. I don't know, John, if you want to comment on that?

Yes. I think we anticipate having when we did the guide, it said it would be a first half, second-half story particularly on services. And we're seeing that in the way that this year is playing out, we'd anticipate to have 49% first half, 51%, 52% second half. And so we typically do see services pick up in the latter part of the year, namely in Q4. And so that's the typical seasonality that we've been referring to and that we saw last year. So we do think that will be a component of how this year plays out also.

Yes. That’s helpful. Thank you. And then maybe sticking on the services bookings side. I guess it sounds like, based on your commentary, they were relatively in line with your expectations, but any comment around what you're looking for in the quarter and then how services bookings in particular stacked up? I know when we talked last quarter you kind of pointed us to 2021 and 2022 from a seasonality perspective. It looks like the average step-down in those years was about 10% sequentially, and they were down about 20% sequentially here in the second quarter of this year. So any comment around just how services bookings kind of stacked up to your expectations here in the second quarter?

Yes. So the services bookings did come in later than we had expected, given the Tier 1 performance of what we had seen. But that being said, services bookings did grow 14% year-on-year. And as we look forward to the second half, the key component is the seasonality that we've seen, and we saw last year importantly. So we're not anticipating anything outsized in that seasonality compared to what we saw last year.

Thank you. Our next question comes from Steve Dechert from KeyBanc. Your line is now open.

Hi, guys. Just wondering if you think the launch of Certara Cloud had an impact on your second quarter bookings. Thanks.

It's still early days, Steve, for Certara Cloud to have a material impact on the bookings. So the answer to that. Although, as we said, our software bookings and our software revenue continue to be strong. We don't see any reason for that to change. And Certara Cloud is a key component of our strategy going forward, and we think that that's going to enable not just that product, but all of the products in our portfolio. But for Q2, that wouldn't have been a meaningful part of our booking.

Thank you. This concludes our question-and-answer session. Thank you for your participation in today's conference. This does conclude our program. You may now disconnect.